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Background: Some psychotropic medications (e.g., benzodiazepines, sedative antidepressants, etc.) may impair
cognitive and psychomotor functions and, therefore, endanger traffic safety (Ravera, Br J Clin Pharmacol,
72(3):505–513, 2011). They affect detection, registration, and information processing, problem solving, and
decision-making processes, and they also affect emotional and social aspects. The objective of this research
was to clarify three closely related issues that are significant for traffic safety: the prevalence of psychotropic
drugs on driving, the most frequently used psychotropic drugs to treat depression, anxiety, insomnia, or any
tranquilizers (whether it is a medical prescription or self-medication), and finally, provide a further understanding of the
socio-demographic and psycho-social characteristics of drivers related to the psychotropic drugs consumption in Spain.
Methods: A sample of 1,200 Spanish drivers ranging from 18 to 64 years was used, 666 men and 534 women were
asked to answer a questionnaire composed by a set of questions structured in different sections. The only selection
criteria were to be in possession of any type of driving license for vehicles other than motorcycles and drive frequently.
Results: The results showed that 15% of the participants were consuming psychotropic drugs to treat depressive
disorders, anxiety disorders, insomnia, or tranquilizers; 13.5% were using drugs to treat one of these disorders; while
1.5% used them for several of these disorders. A 2.5% of drivers were using medicines to treat depression, 2.6% to treat
anxiety, and 3.7% to treat insomnia. The 8.3% of those drivers who were not using any drugs to treat these three
disorders were occasionally using some type of tranquilizers. Benzodiazepines and selective serotonin reuptake
inhibitors (SSRIs) were the most used type of medicines among drivers. Benzodiazepines were the most used
medicines to treat anxiety, while SSRIs were the most used to treat depression, 56.5% and 43.5%, respectively.
Conclusions: Measures can be developed to reduce traffic accidents caused by the effects of these drugs; however,
this will only be possible once the drivers and the use of these drugs are understood. Health care professionals and
patients should be properly informed about the potential effects of some psychotropic medications on driving abilities
considering individual and group differences.
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Many psychiatric disorders may present problems with
driving [1,2]. However, decisions regarding fitness to
drive on psychiatric grounds may be difficult because of
the subjective nature of the symptoms and difficulty in
prediction of disturbed behavior.
Most mental illnesses tend to reduce activity and inter-
est and therefore possibly the use of a car [3]. However, in* Correspondence: datspublications@gmail.com
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Exam Model). The most worrying finding was that ten
participants out of those who were driving were profes-
sional drivers (and only two of them passed the tests).
Moreover, psychiatric drug treatments may cause changes
in perception, information processing and integration, and
psychomotor activity that may disturb and/or interfere
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factors that may affect the ability to drive safely, even
though they are not the main cause of traffic accidents
[7]. Because of that, the high number of drivers who are
under treatment is an aspect of great relevance that af-
fects road safety. In this sense, research has shown that
taking psychotropic drugs can cause a higher risk of get-
ting involved in a traffic accident [8].
The responsibility of psychotropic drugs as a cause of
road traffic accidents remains difficult to evaluate with
precision. Different studies performed in many countries
have provided a certain precision in relation to the per-
centage of injured drivers whose blood contained psy-
chotropic substances (8% to 10% according to studies).
On the other hand, it is practically impossible to really
know either these substances were or were not the cause
of the accidents because underlying or associated path-
ologies may equally create problems such as lack of at-
tention and other vigilance deficits. There is also a
possibility of suicidal or aggressive tendencies [9].
A certain number of circadian and other chronobio-
logical parameters also complicate the problem since the
schedule (hour) as well as the day of the week or even
the season can considerably modify vigilance and reac-
tion time. Available medications able to create such
problems are numerous, and their mechanisms of action
are varied. They may affect vision, impulsiveness, and vigi-
lance. They can act either by direct mechanisms of sed-
ation or, on the contrary, by raising inhibition through
secondary mechanisms: delay in drug elimination or caus-
ing insomnia. For the most part, incriminated medica-
tions belong to the different classes of sedative medicines:
benzodiazepines, antiepileptics, some antihistaminic
agents, some antidepressants, some thymoregulators and
some antihypertensives. If it appears methodologically
impossible that research could ever precisely quantify
the share of responsibility of psychotropic drugs in caus-
ing road traffic accidents, this relation remains highly
probable [9].
It has been known for many years that the use of psy-
chotropic substances, such as alcohol, sedatives, anxio-
lytics, antidepressants, or illicit drugs, has a negative effect
on the ability to drive [10].
Several classes of drugs, including amphetamines, anti-
histamines, cannabis, hypnotics, tranquilizers, and tricyclic
antidepressants, have been shown to impair driving skills
in laboratory tests and driver-simulation studies [11-13].
It is also apparent that drugs in combination with al-
cohol, and multiple drugs, present an even greater risk.
Drug driving is a significant problem, both in terms of a
general public health issue and as a specific concern for
drug users [14]. In fact, either alone or in combination,
alcohol and psychoactive substances increase the risk of
having a traffic accident [10,15-17].Specifically, using antidepressants, benzodiazepines, and
sleeping pills known as Z-drugs are all associated with a
significantly increased risk of car accidents, according to a
study about psychotropic drugs linked to increased car ac-
cidents. It was concluded that participants should be
properly informed of the potential risks associated with
the use of these medicines [1,18].
The Driving under the Influence of Drugs, Alcohol
and Medicines (DRUID) project was an integrative effort
to reduce the danger of alcohol, illicit drugs, and medi-
cines in traffic. Regarding prevalence of medicinal drugs
in European countries, the study conclusions were as
follows:
 Illicit drugs are most prevalent among the
population in the Southern European countries
whereas medicines are most prevalent in the Nordic
countries (Denmark, Norway, Sweden, Finland).
 EU mean, all psychoactive medicines: 1.4%; range
across countries: 0.17%–2.99%).
 The prevalence rate for medicines in Spain was
1.6%.
 Benzodiazepines were the most prevalent medicinal
drug in traffic. Z-drugs were less prevalent. However,
considerable differences between countries were
present.
 The medicinal drugs in general mainly detected
among older female drivers during daytime hours.
 More prevalence in men, in 35–49 years old, roads
(not urban), weekend and holiday in daytime
(working day in dark).
The epidemiology reveals a low risk for injury (1.5–3)
and a higher fatality risk (5–7) for the group of ‘benzodi-
azepines and Z-drugs’. The risk of medicinal opioids is
high for injury (5–8) but lower for a fatality (5) [19,20].
Usually, multiple administration of a psychoactive sub-
stance to naïve subjects leads to adaptation after some
time of use. This means that after some days of use of a
psychoactive substance, the degree of performance impair-
ment decreases. The degree of adaption depends on many
factors, especially the dose and the frequency of use.
The condition in patients is by far even more complex
than the situation during adaption of healthy subjects
because the disease itself might have impairing effects
on performance that might be decreased by the medic-
ament itself. Thus, the impairing effects are determined
by an interaction of these factors. For further discussion
of this problem, see [21].
Study framework
Connections between traffic and illnesses are strong and
complex, and they are beyond the existing relation of
the ability to drive and the probability of being involved
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ness, entails the full self-perceived biopsychosocial state
of well-being [22]. From this approach, road health has
to be treated from a comprehensive perspective, i.e., tak-
ing into account the biological, psychological, and social
aspects [23,24]. Moreover, it is important to understand
the health-related causes of drivers that may impair driv-
ing in order to prevent motor vehicle collisions and, also
important, for drivers to be aware of this risk. So, this is
why the framework of this article was a large-scale pro-
ject on ‘road safety and health’ to raise people's aware-
ness regarding this matter [23-25].
This global research on health and driving used a ques-
tionnaire made up of a set of items in different sections.
First of all, the questionnaire was used to collect socio-
demographic and psychosocial data of drivers.
There were also subsections to collect information re-
lated to four areas: ‘subjective incidence of health in
driving’, ‘drivers' psychological state (condition)’ (includ-
ing symptom scales for depression, fatigue, anxiety, and
daily and work stress), ‘medication and driving’, and ‘the
system of selection of drivers’ (view and proposal).
The study described in this article is based on the data
found in the section ‘medication and driving’. In the sec-
tion of the questionnaire, participants were asked whether
they were under pharmacological treatment for anxiety,
depression, or insomnia. If not, they were asked whether
they were using tranquilizers occasionally. If so, they were
asked to state the type of medicine used and whether it
had been prescribed by a doctor. In addition, in order to
understand the perception of drivers about how medicines
treat depression, anxiety, insomnia, or tranquilizers affect
driving, they were asked whether they thought that these
medicines could affect their driving. It was also interesting
to learn about their perception regarding the amount of
information they had about medicine use and how did
they learn about the influence of medicines on driving.
The relationship between different treatments, type of
medicine, and medical prescription was also analyzed in
the global research [25].
Objective
The specific objectives of this survey were as follows:
1. To know the prevalence of psychotropic drugs
(drugs to treat depression, anxiety, insomnia, or
other tranquilizers) in drivers.
2. To identify the most used type of drug
3. Provide a further understanding of the socio-
demographic and psychosocial characteristics of drivers
related to the psychotropic drugs consumption.
In general terms, these aspects will be used to design
interventions and to increase road safety.Method
Participants
Participants were part of a wide-ranging research on dif-
ferent aspects of health that affect driving. The sample
used was composed of 1,200 Spanish drivers ranging from
18 to 64 years, 666 men (56%) and 534 women (44%). The
starting sample size was proportional by quota to the
Spanish population segments of age and gender. The num-
ber of participants represents an error margin for the gen-
eral data of ±2.9 with a 95% confidence interval in the
most unfavorable case of p = q = 50%.
Drivers completed a telephone-based survey. Interviews
were completed for 1,200 drivers, and the response rate
was 92.8%; as it was a survey dealing with social matters,
the vast majority of people wanted to collaborate. There
were 93 (7.2%) people who did not want to participate in
the interview.
Procedure and design
The survey was conducted by telephone. A national tele-
phone household sample was constructed using random
digit dialing. Each household was screened to determine the
number of adult (age 18 or older) drivers in the household.
The only selection criteria were to be in possession of any
type of driving license for vehicles other than motorcycles
and drive frequently. One eligible driver was systematically
selected in each eligible household by the interviewers.
The survey was conducted using the computer-assisted
telephone interviewing (CATI) system to reduce interview
length and minimize recording errors, guaranteeing at all
times the anonymity of the participants, and stressing on
the fact that the data would only be used for statistical
and research purposes. The importance of answering hon-
estly to all the arisen questions was emphasized, as well as
the non-existence of wrong or right answers.
In this article, the data obtained was analyzed in the
questions as follows: ‘Are you currently under pharmaco-
logical treatment for any of these ailments? Anxiety, de-
pression or insomnia’. The participants answered ‘yes’ or
‘no’ for each disorder. If their answer was ‘no’ for all of
them, they were asked: ‘Do you occasionally use any drug
or pill to relax?’. If their answer was ‘yes’, in anyone, they
were asked to say the type of medicine they used.
First of all, the questionnaire was used to collect data to
establish a profile of the interviewed as a driver, with the
aim of detecting the distinguishing characteristics that de-
fine their inclusion into a certain group(s). These variables
mainly focused on socio-demographic and psychosocial
characteristics grouped in the following subsections.
Demographic variables
The following are the demographic variables:
 Sex (man or woman)
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56–65, over 65)
 Population size where they live (strata considered
are as follows: in less than 10,000; from 10,001 to
20,000; 20,001 to 100,000; 100,001 to 500,000; and
more than 500,000)
 Work activity (grouped in active, not active,
housework)
 Profession (grouped in self-employed, management,
other employees employed)
 Working time (day, night, and shifts)
Driving habits
The following are the driving habits:
 Day/night driving (by day, by night, either).
 Continuous driving by journey (grouped in less than
1 h; for 1 to 2 h; 2 or more hours).
 Type of road more frequently used for driving
(grouped in urban zones; conventional roads;
highway).
 Type of vehicle used (grouped in utilitarian vehicles—
conventional cars, sports cars, and family—and
commercial or transportation vehicles such as vans,
trucks, buses, etc.
 Risk exposure. To determine the level of risk
exposure of the driver interviewed, both the average
miles driven per year as well as the frequency driven
were taken into account. The combination of both
variables have led to a classification of drivers in five
groups:
Exposure to very low risk: includes mainly
sporadic drivers (low frequency and/or few
km/year).
Exposure to low risk: includes drivers who made
sporadic but long trips (e.g., vacation) or even
those who drive frequently but made very few
kilometers per year.
Average risk exposure: includes regular drivers
who do not average many kilometers per year
as their movements are not excessively long
(e.g., urban trips or weekend outings).
Exposure to high risk: includes the usual
drivers averaging significant kilometers
per year because their movements are
relatively long (i.e., their commute to
and from work).
Exposure to very high risk, including those who
drive frequently and that in turn make many
kilometers per year (e.g., professional drivers,
commercial, delivery, etc.).
 Reason for driving. Grouped in itinere (on the
way to or from work), during work, leisure,
and/or personal, regardless labor or leisure).Experience/risk
The following are the experiences/risks:
 Years of driving experience. Experience has been
defined as the time that the respondent has been
driving on a regular basis. This variable is
complementary to the risk exposure, since both
variables are an indicator of learning situations (both
positive and negative) that the respondent has been
able to experience in their driving history. (Grouped
in less than 1 year, 1–2 years, 3–10 years, 11–20,
21–30, over 30 years).
 Risky behavior. The risky taking is calculated by five
items. The objective of this set of items is to rate
drivers for certain risk behaviors (exceeding speed
limits and not keep a safe distance, making a rushed
or improper pass, driving after drinking alcohol,
using a mobile while driving without using a
hands-free device). For each behavior considered
have applied the classification criteria of risk-no risk
used in the study SARTRE 3 [26], depending on
how often they engaged in these behaviors. Taking
these criteria into account, drivers have been
classified into three groups:
‘No Risk’ group: drivers that have not been
classified in any of the risk behaviors considered.
‘Medium risk’ group: drivers who have been
classified in one or two risk behaviors considered.
‘High risk’ group: drivers of risk are classified in
more than one of the considered behaviors.
 Traffic violations. Number of penalties received in
the last 3 years, excluding parking offenses (none,
one, more than one penalty).
 Crash history. Number of accidents occurring
throughout a driver's life, focusing primarily on
accidents suffered as a conductor (none, one, more
than one accident).
Once the data was obtained, the relevant statistical
analyses were carried out with the Statistical Package for
the Social Sciences (SPSS).
Results
The results showed that 15% of the participants were con-
suming psychotropic drugs, to treat depressive disorders,
anxiety disorders, insomnia disorders, or tranquilizers;
13.5% were using drugs to treat one of these disorders;
while 1.5% used them for several of these disorders.
A 2.5% of drivers were using medicines to treat depres-
sion, 2.6% to treat anxiety, and 3.7% to treat insomnia.
The 8.3% of those drivers who were not using any drugs
to treat these three disorders were occasionally using
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Figure 1 Percentage distribution of drivers using drugs to treat depression, anxiety, stress, or tranquilizers.
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(x2 = 8.101, p ≤ 0.005), and age (x2 = 13.666, p ≤ 0.05)
among the 2.5% of drivers that were being treated for
depression; women (70% of the interviewed drivers under
treatment for depression) and adults (46–55) used drugs
more often than any other age group. Table 1 shows the
frequency and percentage of people with or without
depression medication classified according to their gen-
der or age.
Regarding anxiety, adults ranging from 36 to 45 years
(x2 = 13.306, p ≤ 0.05) were the group that most used anx-
iety medication, even though the percentage of driversTable 1 Frequency and percentage of people with or
without depression medication classified according to










Gender Women 21 3.9 513 96.1
Men 9 1.4 657 98.6
Age 18–25 0 0 125 100
26–35 4 1.5 261 98.5
36–45 11 3.2 335 96.8
46–55 12 5.2 220 94.8
56–65 3 1.7 169 98.3
> 65 0 0 60 100that were being treated for this disorder was small (2.6%).
However, it was not possible to establish a significant rela-
tionship between gender and drug use to treat this dis-
order. Table 2 shows the frequency and percentage of
people with or without anxiety medication classified ac-
cording to their gender or age.
By contrast, adults ranging from 56–65 years took
more drugs to treat insomnia, even though the differ-
ences in these groups did not reach the level of import-
ance required (x2 = 10.229, p ≤ 0.07). In this case, it was
not possible to establish a significant relationship be-
tween gender and drug use to treat this disorder. Table 3Table 2 Frequency and percentage of people with or











Gender Women 19 3.6 515 96.4
Men 12 1.8 654 98.2
Age 18–25 2 1.6 123 98.4
26–35 3 1.1 262 98.9
36–45 17 4.9 329 95.1
46–55 7 3.0 225 97.0
56–65 2 1.2 170 98.8
> 65 0 0 60 100
Table 3 Frequency and percentage of each gender and










Gender Women 22 4.1 512 95.9
Men 22 3.3 644 96.7
Age 18–25 2 1.6 123 98.4
26–35 5 1.9 260 98.1
36–45 11 3.2 335 96.8
46–55 13 5.6 219 94.4
56–65 11 6.4 161 93.6
> 65 2 3,3 58 96.7
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each age group with or without insomnia medication.
Likewise, tranquilizers are used by 8.3% of the drivers
who were not using drugs to treat depression, anxiety, or
insomnia; adults ranging from 56–65 used these drugs
more often. In this case, it was not possible to establish a
significant relationship between gender and drug use.
Therefore, information in Table 4 shows the frequency
and percentage of different gender and age groups with or
without tranquilizers.
Regarding the significative relationship between vari-
ables related to driving, experienced drivers, 11–20 years
of experience (4%, n = 12) and 21–30 years of experience
(4.2%, n = 12), and drivers who drive ‘regardless labor or
leisure’ (4.3%, n = 16) have a higher percentage of drivers
under treatment for depression. On the other hand, men
(98.6%, n = 657), young people, 18–25 years old (100%,
n = 125), drivers with 3–10 years of experience (99.3%,
n = 275), or with more than 30 years (99.5%, n = 214), those
who use their vehicle for ‘personal and/or leisure’ (98.6%,
n = 419) and during work (98.7%, n = 220), and those whoTable 4 Frequency and percentage of different gender
and age groups with or without tranquilizers






Gender Women 41 8.5 444 91.5
Men 51 8.1 577 91.9
Age 18–25 6 5.0 115 95.0
26–35 21 8.3 233 91.7
36–45 23 7.3 294 92.7
46–55 17 8.3 189 91.7
56–65 20 12.7 137 87.3
> 65 5 8.6 53 91.4drive in daylight (98%, n = 887) are the groups in which
there are high percentages of drivers who are not under
treatment for depression. It was not possible to establish a
significant relationship between size of town, risk expos-
ure, type of vehicle, hours of non-stop driving in usual
commutes, most frequently used type of road, crashes,
sanctions over the last 3 years (except parking tickets), risk
assumed, working status, profession, or work schedule.
Regarding anxiety, drivers who live in towns with more
than 500,000 people (6.1%, n = 12), and adults ranging
from 36–45 years (4.9%, n = 17) are the groups with a big-
ger number of people under treatment for this disorder,
even though the total percentage of drivers for it is small
(2.5%). In contrast, active workers (98.1%, n = 819), and
people living in towns with no more than 10,000 people
stated (99.3%, n = 217) they were using medicines for this
disorder less frequently.
It was not possible to establish a significant relation-
ship between age, type of vehicle, risk exposure, driving
experience, reasons for the journey, daylight/night driving,
hours of non-stop driving in daily commutes, most fre-
quently type of road, crashes, sanctions over the last 3 years
(except parking tickets), risk assumed, and profession.
On the other hand, the percentage of people using
medicines to treat insomnia is slightly higher (3.7%). The
number of people ranging from 36–45 years (3.2%, n = 11),
46–55 years (5.6%, n = 13), 56–65 years (6.4%, n = 11) are
the groups with a bigger number of people under treat-
ment for this disorder. The percentage of active workers
using medicines to treat insomnia is 2.4%, n = 20, while this
percentage increases until 6.6%, n = 18, for the group of
unemployed people (Figure 2).
It was not possible to establish a significant relation-
ship between size of town, gender, risk exposure, type of
vehicle, driving experience, reasons for the journey, day-
light/night driving, hours of non-stop driving in daily
commutes, most frequent type of road, crashes, sanc-
tions over the last 3 years (except parking tickets), risk
assumed, profession, and work schedule.
Finally, it is important to remember that 8.3% of drivers
(only taking into account those who do not use medicines
to treat depression, anxiety or insomnia) stated they were
sometimes using tranquilizers. The use of these medicines
is more frequent in drivers living in towns of 10,000–
20,000 people (12.8%, n = 16) and in drivers ranging from
56–65 years (12.7%, n = 20).
Regarding the variables related to driving, drivers with
an average risk exposure (12.1%, n = 29), those drivers
with more than 30 years of driving experience (13.9%,
n = 28), and those who drive non-stop for 1 or 2 h (14.1%,
n = 23, of drivers in this last group used tranquilizers)
were the groups that used tranquilizers more frequently
(Figure 3). In addition, they were drivers who were sanc-
tioned over the last 3 years (except parking tickets)
2.4 6.6 6.5 3.7
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%




Figure 2 Drivers with insomnia according to their working status, and comparison with the general distribution.
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who worked on their own (10.7%, n = 17).
However, the probability of using tranquilizers was
smaller for those drivers who were active workers (93.1%,
n = 733), less than 1 h in the continuous driving by jour-
ney (92.6%, n = 793).
It was not possible to establish a relationship between
the use of tranquilizers and gender, type of vehicle, rea-
sons for the journey, type of road, daylight/night driving,
crashes, risk assumed, or work schedule.
Regarding the type of medicines, these are the most fre-
quently used among drivers interviewed: benzodiazepines
to treat anxiety (56.5%), to treat insomnia (35.7%), and de-



















Figure 3 Drivers using tranquilizers or not according ‘hours non-stopserotonin reuptake inhibitors (SSRIs) were used to treat
depression (43.5%), anxiety (26.1%), insomnia (3.6%), and
as tranquilizers (1.5%) (Figure 4). The table below shows
the most frequently used medicines classified according to
their specification (Table 5).
Discussion
The fact that a high percentage of people (15%) use
drugs to treat depression, anxiety, insomnia, and tran-
quilizers shows that this group of drivers is a risk for
road safety since these psychotropic drugs.
These prevalence data are more important if possible, as
they are higher than the results of the DRUID project (re-
member that according to this project, prevalence rate for7.8 8.4
92.2 91.6
2 or more hours Total





























Figure 4 Most frequently used antidepressant drugs to treat the different disorders in this research.
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Spain closest to the group of countries with higher
risk as happens in the case of illicit drugs and alcohol.
The distinct methodology used to obtain them is the
cause of the differences between the data of the studies
(for this section, we use the results of the DRUID project
which relate to the prevalence determined by ‘roadside
surveys (RSS)’ on drivers and in drivers who have been
injured/killed in traffic accidents (hospital studies (HS)).
The fact that 8.3% of those drivers who were not using
any drugs to treat these three disorders were occasion-
ally using some type of tranquilizers (7.7% of the total
drivers interviewed), may involve a more difficult adap-
tation (recall that according Berghaus says in a report
of the DRUID project, the degree of adaption depends
on many factors, especially the dose and the frequency
of use).
The fact that more women than men use more drugs
to treat depression is also a coinciding data with those
determined in the DRUID project on a general level. In
the case of the anxiety and tranquilizers in our study, it
was not possible to establish a significant relationship
between these variables.
It also seems clear that, regarding the age, people be-
tween 36–45 use more drugs to treat anxiety and 46–55
use more drugs to depression. Aged 56–65 use drugs to
treat insomnia and tranquilizers.
Given the different nature of other studies, it is diffi-
cult to make comparisons in the case of age as well as
the type of road (roads/cities) and the time of displace-
ment (workday, weekend, holiday, daytime).
Furthermore, other socio-demographic and psycho-
social characteristics cannot be contrasted because those
have not been contemplated by previous studies.
The fact is that drugs containing benzodiazepine are the
most used drugs to treat all the disorders in the studyamong the drivers interviewed and corresponds with data
obtained in the DRUID project and other studies.
However, in our study, the results are also very im-
portant on the consumption of different drugs at the
same time.
The combined used of drugs for the three conditions
studied (depression, anxiety, and insomnia) must also be
taken into account since these conditions are usually re-
lated to one another thus leading drivers to use medicines
for more than one condition (insomnia and anxiety, 29%
of the drivers; depression and anxiety, 20%; insomnia and
depression, 17%).
Conclusions
In order to prevent traffic crashes, it is necessary to in-
form drivers using drugs about the effects they may have
on driving and more much control (both the health sys-
tem and the police).
We propose creating and implementing a wide range
of formal intervention strategies. This can be achieved
by using general communication campaigns and adver-
tising in order to inform and teach drivers about the in-
fluence of several psychotropic drugs on driving.
It is a fact that there are many campaigns on other sub-
stances such as alcohol and illicit drugs but much less on
psychotropic medications.
The data obtained in this study according to socio-
demographic and psychosocial characteristics are very
important for the design and dissemination of such cam-
paigns. And it is for both determining the target audi-
ence to the communication of certain risk behaviors in
Spain.
Standardized warning labels on medicine boxes and
package inserts sold in all countries should be imple-
mented as an important countermeasure (have already
been implemented in Spain).
Table 5 Percentage distribution of medicines used by
drivers who were under treatment for different disorders
Medicines used by drivers who were under
treatment for different disorders
Percentage
Drugs to treat depression
Antidepressant 60.9%
Selective serotonin reuptake inhibitors (SSRI) (43.5%)
Antidepressant tretracyclics (8.7%)











Selective serotonin reuptake inhibitors (SSRI) (26.1%)
Serotonin and noradrenaline reuptake inhibitors (8.7%)
Hypnotic-sedatives 4.3%
Other hypnotic-sedatives (4.3%)









Selective serotonin reuptake inhibitors (SSRI) (3.6%)
Tricyclic antidepressants (TCAs) (7.1%)







Anti-inflammatory and analgesic drugs 20.6%
Antidepressants 2.9%
Selective serotonin reuptake inhibitors (SSRI) (1.5%)
Serotonin and noradrenaline reuptake inhibitors (1.4%)
Distribution of different active principles based on their specific action.
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mary health care doctors, health care specialists, phar-
macists, psychiatrics, and psychologists) get involved in
informing drivers about the side effects (cognitive and
psychomotor deterioration) of using psychotropic drugs,
as well as the serious consequences of self-medication.
In order to minimize side effects affecting daily activ-
ities, it is necessary that health professionals prescribe
drugs (specific components, route of administration,
avoiding certain associations, and establishing the dose)
according to the vital and professional needs of the pa-
tient. Some of these demands are related to driving vehi-
cles, specifically when it comes to professional drivers
and drivers making daily commutes.
In this sense, the results of this study for Spanish
health professionals are very important because socio-
demographic and psychosocial characteristics can help
identify high risk group. It is also important for police
supervision as it can decide better the controls to be
made on this behavior both temporally and spatially.
Likewise, it is also necessary to regulate the fact that
driving should not be allowed while certain drugs are be-
ing used. It would be interesting to authorize doctors to
determine, if necessary, those drivers who may be im-
paired due to the treatment with certain drugs thus low-
ering road safety.
In this sense, it is very important to establish better
communication and collaboration between the health
system (hospitals, health centers, etc.) and recognition
center conductors (regulated in Spanish Medical and
Psychotechnical Exam Model), as the seconds, given the
time between recognitions (which only occur in obtain-
ing and renewing the license) cannot detect transient
risks such as those that can be derived from the use of
these substances.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
FA elaborated the design of the study with the help of CE; the rest of the
authors also contributed. FT and LM were in charge of the data revision.
CE also drafted the manuscript. FA performed the statistical analysis.
All authors read and approved the final manuscript.
Acknowledgements
The authors wish to thank the Audi's program of Corporate Social
Responsibility, Attitudes for the patrimony of the basic research. Also thanks
to Mayte Duce for the revisions and to Catalina Pardo and Jose Colomer for
the revision of the English text.
Author details
1DATS (Development and Advising in Traffic Safety) Research Group, INTRAS
(Research Institute on Traffic and Road Safety), University of Valencia, Serpis
29, Valencia 46022, Spain. 2FACTHUM.lab (Human Factor and Road Safety),
INTRAS (University Research Institute on Traffic and Road Safety), University
of Valencia, Serpis 29, Valencia 46022, Spain. 3PRECOVIR (Prevention of Risk
Behavior on the Road), INTRAS (Research Institute on Traffic and Road
Safety), University of Valencia, Serpis 29, Valencia 46022, Spain.
Alonso et al. Annals of General Psychiatry 2014, 13:14 Page 10 of 10
http://www.annals-general-psychiatry.com/content/13/1/14Received: 12 December 2013 Accepted: 23 April 2014
Published: 8 May 2014References
1. Ravera S, van Rein N, de Gier JJ, de Jong-van den Berg LT: Road traffic
accidents and psychotropic medication use in the Netherlands:
a case–control study. Br J Clin Pharmacol 2011, 72(3):505–513.
2. Metzner JL, Dentino AN, Godard SL, Hay DP, Hay L, Linnoila M: Impairment
in driving and psychiatric illness. J Neuropsychiatry Clin Neurosci 1993,
5(2):211–220.
3. Gibbons TCN: Mental illness, personality and behaviour disorders.
In Medical Aspects of Fitness to Drive. 3rd edition. Edited by Raffle PAB.
London, England: Medical Commission on Accident Prevention;
1976:30–33.
4. De las Cuevas C, Sanz EJ: Fitness to drive of psychiatric patients. Prim Care
Comanion J Clin Psychiatry 2008, 10(5):384–390.
5. Harris MC: Psychotropic medication and driving. Psychiatry Pract 1997,
16:5–7.
6. Odell M: Assessing fitness to drive, part 2. Aust Fam Physician 2005,
34(6):475–477.
7. Montoro L, Alonso F, Esteban C, Toledo F: Manual de seguridad vial: El factor
humano. Barcelona. Spain: Ariel; 2000.
8. Wang CC, Kosinski CJ, Schwartzberg JG, Shanklin AV: Medical conditions
and medications that may impair driving. In Physician’s Guide to Assessing
and Counseling Older Drivers. Washington, DC: National Highway Traffic
Safety Administration; 2003.
9. Lemoine P, Ohayon M: Abuse of psychotropic drugs during driving.
L'Encéphale 1996, 22(1):1–6.
10. Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, Lagarde E:
The impact of medicinal drugs on traffic safety: a systematic review
of epidemiological studies. Pharmacoepidemiol Drug Saf 2009,
18(8):647–658.
11. O’Hanlon JF, Volkerts ER: Hypnotics and actual driving performance.
Acta Psychiatr Scand 1986, 74(332):95–104.
12. Smiley A: Effects of minor tranquilizers and antidepressants on
psychomotor performance. J Clin Psychiatry 1987, 48:22–28.
13. Robbe H: Marijuana’s impairing effects on driving are moderate when
taken alone but severe when combined with alcohol. Hum Psychopharm
Clin 1998, 13(2):70–78.
14. Kelly E, Darke S, Ross J: A review of drug use and driving: epidemiology,
impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004,
23:319–344.
15. Engeland A, Skurtveit S, Morland J: Risk of road traffic accidents
associated with the prescription of drugs: a registry-based cohort
study. Ann Epidemiol 2007, 17(8):597–602.
16. Movig KL, Mathijssen MP, Nagel PH, van Egmond T, de Gier JJ, Leufkens HG,
Egberts AC: Psychoactive substance use and the risk of motor vehicle
accidents. Accid Anal Prev 2004, 36(4):631–636.
17. Verster JC, Mets MA: Psychoactive medication and traffic safety. Int J
Environ Res Public Health 2009, 6(3):1041–1054.
18. Smink BE, Egberts AC, Lusthof KJ, Uges DR, de Gier JJ: The relationship
between benzodiazepine use and traffic accidents: a systematic
literature review. CNS Drugs 2010, 24(8):639–653.
19. Schulze H, Schumacher M, Urmeew R, Auerbach K: DRUID Final Report: Work
Performed, Main Results and Recommendations. http://www.druid-project.eu.
20. Hargutt V, Krüger H-P, Knoche A: Driving Under the Influence of Alcohol, Illicit
Drugs and Medicines. Risk Estimations from Different Methodological
Approaches, DRUID deliverable 1.3.1. 2011. http://www.druid-project.eu.
21. Berghaus G, Sticht G, Grellner W, Lenz D, Naumann T, Wiesenmüller S:
Meta-Analysis of Empirical Studies Concerning the Effects of Medicines and
Illegal Drugs Including Pharmacokinetics on Safe Driving. 2010. EU Project
DRUID, WP 1, Deliverable 1.1.2b.
22. Gee GC, Takeuchi DT: Traffic stress, vehicular burden and wellbeing:
a multilevel analysis. Soc Sci Med 2004, 59:405–414.
23. Alonso F, Esteban C, Calatayud C, Alamar B, Egido A: Salud Vial. Teoría y
prácticas de los trastornos físicos y psíquicos en la conducción. Cuadernos de
Reflexión Attitudes. Valencia, Spain: Intras; 2008.
24. Alonso F, Sanmartín J, Esteban C, Calatayud C, Alamar B, López E: Salud Vial.
Diagnóstico de los conductores españoles. Cuadernos de Reflexión Attitudes.
Valencia, Spain: Intras; 2008.25. Alonso F, Esteban C, Calatayud C, Alamar B, Fernández C, Medina JE:
Conclusiones de las 7as jornadas de reflexión Attitudes: Salud vial ¿el
conductor a terapia? Cuadernos de Reflexión Attitudes. Valencia, Spain:
Intras; 2008.
26. Sánchez F: Actitudes frente al riesgo vial. Intervención Psicosocial 2008,
17(1):45–59.
doi:10.1186/1744-859X-13-14
Cite this article as: Alonso et al.: Psychotropic drugs and driving:
prevalence and types. Annals of General Psychiatry 2014 13:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
